Filing Flows › Neurocrine Biosciences (NBIX) › Operating margin
Neurocrine Biosciences (NBIX) operating margin by quarter
Neurocrine Biosciences' operating margin was 29.5% in Q3 2026 (third quarter 2026), +13.7 pts from Q2 2026. Over the last 7 quarters it ranged from 4.1% (Q1 2025) to 30.1% (Q3 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 29.5% | +13.7 pts | -0.6 pts |
| Q2 2026 | 15.8% | -7.9 pts | -5.4 pts |
| Q1 2026 | 23.7% | -2.4 pts | +19.6 pts |
| Q4 2025 | 26.2% | -3.9 pts | — |
| Q3 2025 | 30.1% | +8.9 pts | — |
| Q2 2025 | 21.2% | +17.1 pts | — |
| Q1 2025 | 4.1% | — | — |
Q3 2026 at a glance
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neurocrine Biosciences' operating margin?
Neurocrine Biosciences' operating margin was 29.5% in Q3 2026 (third quarter 2026), +13.7 pts from Q2 2026.
How has Neurocrine Biosciences' operating margin changed?
Over the last 7 quarters it ranged from 4.1% (Q1 2025) to 30.1% (Q3 2025).
Q3 2026 results → · How Neurocrine Biosciences makes money →